70 Gene signature

Nie AY, McMillian MK, Leone AM, Parker JB, Piechta L-A, Bryant S, et al. A gene signature for non-genotoxic carcinogens. Society of Toxicology, 2005. 

Pena, S.D.J., Barreto, G., Vago, A.R., de Marco, L., Reinach, F.C., Dias-Neto, E. and Simpson, A.J.G. (1994) Sequence-specific gene signatures can be obtained by PCR with single specific primers at low stringency. Proceedings of the National Academy of Sciences USA 91, 1946-1949. 

Microarray analyses of breast cancer have identified unique gene expression profiles associated with patient survival. Sorlie et al. (23) found the expression profiles to distinguish ER-i- from ER- tumors with distinct outcomes in a cohort with locally advanced breast cancer treated with primary chemotherapy. Van t Veer et al. (18) established a 70-gene signature to predict metastatic potential in an untreated, node-negative cohort. Sotiriou et al. (24) showed the concordance with these previous analyses in node-positive and node-negative patients with the majority receiving adjuvant treatment. 

The U.S. FDA recently approved the first gene test for cancer, MammaPrint (the 70-gene signature) of Agendia (Amsterdam, the Netherlands) (18), for node-negative women under 61 years of age with primary breast cancer tumors. 

Oncotype DX (a 21-gene signature) of Genomic Health (Redwood City, CA) is another commercially available gene test for breast cancer. It is currently applied in clinics to predict recurrence of tamoxifen-treated, node-negative, and estrogen-receptor-positive breast cancer (28). 

Brazas MD, Hancock RE. Using microarray gene signatures to elucidate mechanisms of antibiotic action and resistance. Drug Discov Today 2005 10(18) 1245-1252. 

Computational Methods to Achieve Gene Expression Profiling and Find Gene Signatures 375... 

Gene signatures can be found using three main computational approaches DE, class assignment and prediction based on expression, and class discovery based on expression. 

Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007 356(3) 217-26. 

Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007 356(l) ll-20. 

Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005 106 1392-1399. 

Finkelstein, D., Lamba, V., Assem, M., Rengelshausen, J., Yasuda, K., Strom, S., and Schuetz, E. (2006) ADME transcriptome in hispanic versus white donor livers evidence of a globally enhanced NR 113 (CAR, constitutive androstane receptor) gene signature in hispanics. Xenobiotica 36, 989-1012. 

---